Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Treatment of Gastric Cancer With Limited Peritoneal Metastasis, ROBO-CHIP Study
Eligible age
18–80 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This phase II clinical trial tests how well robotic cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) in treating patients with gastric cancer that has spread to the tissue that lines the wall of the abdominal cavity (peritoneum). Gastric cancer is the third leading cause of cancer related deaths worldwide and peritoneal metastasis are found in 30% of patients at time of diagnosis. Patients with peritoneal metastasis have poor survival rates. Traditional surgery is done with a large incision and has a high complication rate and longer hospital stays. Robot assisted (robotic) cytoreduction is a surgical option that uses small incisions and there is less risk of complications. HIPEC involves infusing heated chemotherapy into the abdominal cavity during surgery. Robotic cytoreduction together with HIPEC may improve recovery and decrease complications after surgery.
Sponsor: Mayo Clinic
You may qualify if…
- ✓ Restricted to 18 to 80 years of age
- ✓ Eastern Cooperative Oncology Group (ECOG) performance status =\< 2
- ✓ Histologic confirmation of gastric adenocarcinoma including all subtypes and Siewert type II/III gastroesophageal (GE) junction adenocarcinomas
- ✓ Absolute neutrophil count \>= 1,500 / uL
- ✓ Platelets \>= 50,000 / Ul
- ✓ Serum creatinine \<= 1.5 mg / dL
- ✓ Adequate nutritional status (Albumin \>= 3.5)
- ✓ Metastasis confined to the peritoneum:
You may not qualify if…
- ✕ Distant metastatic disease not limited to peritoneum, such as solid organ metastases (liver, lung, bone, distant lymph node, etc)
- ✕ Malignant ascites at time of study enrollment
- ✕ Comorbidities that would preclude protocol therapy
- ✕ Subjects deemed unable to comply with study and/or follow-up procedures
- ✕ Subjects with a known hypersensitivity to protocol systemic chemotherapy that was life-threatening, required hospitalization or prolongation of existing hospitalization, or resulted in persistent or significant disability or incapacity
Where it's recruiting
Rochester
Source: ClinicalTrials.gov · NCT05753306 · last updated 2026-04-08